HUM

HUMANA INC

Healthcare | Large Cap

$10.45

EPS Forecast

$39,365

Revenue Forecast

The company already released most recent quarter's earnings. We will publish our AI's next quarter's forecast around 2026-07-20

Humana’s 1Q26: Two EPS, One Guidance Roadmap, and a CenterWell Growth Engine

Overview: the numbers, the guidance split, and the growth levers

Humana Inc. (ticker: HUM) reported first-quarter results for 2026 that underscored a familiar dynamic in health-insurance earnings: a solid front-end EPS print on a GAAP basis, paired with a stronger non-GAAP figure once adjustments are stripped away. The company posted 1Q26 GAAP EPS of $9.83 and 1Q26 adjusted EPS of $10.31, with management noting that revenue trends remain on a trajectory that supports its full-year plan. In a move that will invite analysts to compare apples and apples, Humana affirmed its full-year EPS" target landscape—specifically, a near-term EPS emphasis on adjusted results—while revising its GAAP EPS guidance to a lower floor.

On the operational side, Humana highlighted continued momentum in its Medicare Advantage membership growth—roughly a 25% increase over 2025—driven by sales and retention improvements under its customer-led strategy. The quarter also showcased the growth engine around CenterWell, including the MaxHealth acquisition, and continued expansion within state-based contracts. The release reiterates that investors should focus on the dual narratives of GAAP versus adjusted earnings, and how those figures align with the company’s revenue forecast and outlook.

Guidance and the two EPS narratives

Humana’s guidance commentary reflects a split between GAAP and adjusted metrics. The company affirms FY 2026 guidance for adjusted earnings per share of at least $9.00, signaling that the non-GAAP view remains central to how management frames profitability. At the same time, management revises its GAAP EPS guidance to at least $8.36, down from a prior mark of at least $8.89. This divergence—strong adjusted EPS versus modestly tempered GAAP EPS—is not unusual in healthcare services where non-cash items, acquisition-related amortization, or other GAAP adjustments can swing reported earnings independently of the core business.

Investors and analysts will likely parse whether the gains implied by the 1Q EPS outturn were propelled by one-time or non-operational factors, or whether they point to a durable earnings trajectory. The press release does not publish an explicit EPS consensus target in the excerpt, but the discrepancy between GAAP and adjusted figures will be a focal point for the earnings surprise narrative if subsequent quarters diverge from expectations. In the near term, the shares will be judged on whether the adjusted framework continues to near the high end of guidance or if future quarters reveal a tightening of the GAAP baseline.

Growth engines: MA membership, CenterWell, and state-based contracts

The company’s metrics reinforce a narrative of growth through scale and integration. Medicare Advantage membership growth of about 25% over 2025 is cited as a contributor to earnings resilience, supported by a customer-led services approach and improved retention. Within the CenterWell ecosystem, Humana reports a sequential expansion of 110,500 patients—roughly a 22% rise—with notable progress from the MaxHealth acquisition, including around 59,000 patients and 54 centers linked to the deal. The combination of CenterWell’s health services footprint and MaxHealth’s assets seems designed to broaden Humana’s national coverage and service capabilities.

The State-based contracts program is another growth vector, with 1Q26 membership growth of approximately 50,000 across these contracts. Taken together, the mix of MA growth, CenterWell expansion, and new state-based programs suggests a strategy to diversify enrollment beyond traditional Medicare Advantage membership and to deepen operating leverage across care delivery and administrative platforms.

Impressions for peers and the sector

Humana’s quarter-to-quarter cadence highlights a broader theme in managed healthcare: the value of aligning earnings metrics with cash-generative, patient-facing growth initiatives while maintaining a conservative GAAP posture. For peers in the Medicare Advantage and integrated care space, the message is clear: investment in care delivery networks and strategic acquisitions can support strong adjusted earnings even as GAAP results carry more volatility.

Sector watchers will note the emphasis on membership mix, the cost-and-benefit structure of the Insurance segment (the benefit ratio stood at 89.4% in the quarter, slightly favorable versus guidance of “just under 90%”), and the ongoing execution of growth initiatives across CenterWell and state-based contracts. These elements will shape how competitors model their own revenue forecast trajectories and how they calibrate the balance between EPS discipline and strategic investments.

Investor communications and where this goes from here

The company signaled continued transparency by noting the publication of prepared management remarks on Humana’s Investor Relations page ahead of an 8:00 a.m. ET Q&A session. In practical terms, investors may be listening for how the GAAP vs. adjusted earnings story evolves across the year, how the CenterWell integration contributes to margins, and whether the MA membership trajectory sustains its pace.

The juxtaposition of a strong EPS print under a robust adjusted framework with a slightly tempered GAAP floor creates a nuanced set of expectations for the sector. If Humana sustains its adjusted EPS trajectory and the State-based contracts and CenterWell expansions translate into durable cash generation, peers in health plans and care-delivery platforms may emulate the strategy—leveraging integrated services to support earnings resilience even as GAAP headlines swing with macro and regulatory inputs.

Conclusion: a measured step forward with a growth engine in motion

Humana’s first-quarter results for 2026 illustrate a disciplined approach to earnings: a compelling adjusted EPS narrative, strategic growth through CenterWell and acquisitions like MaxHealth, and a recalibration of GAAP EPS targets to reflect ongoing normalization and programmatic investments. The fiscal path, as laid out, points toward continued earnings strength under the adjusted framework, with the GAAP headline carrying more volatility—an invitation for earnings surprises to emerge if quarterly dynamics tilt away from the baseline assumptions.

For investors tracking HUM and the broader health-services cohort, the quarter offers a clear signal: leverage from membership growth, care-network expansion, and diversified contracts can underpin durable cash generation and a path to higher EPS under the right accounting lens. As always, the proof will be in the quarters ahead—and the degree to which management can translate CenterWell’s added scale into steady margins will determine whether 2026 becomes a period of consolidation or a springboard for further expansion.